|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Outcome indicators for vitrectomy in Terson syndrome显示文摘 | Garweg JG Koerner F | 2009 | Acta Ophthalmol2009，87，： | 1 |
| 2 | Safety and efficacy ofranibizumab in diabetic macular edema ( RESOLVE Study) : a 12-month ,randomized, controlled, double-masked, multicenter phaseII study 显示文摘 | Massin P Bandello F Garweg JG | 2010 | Diabetes Care2010，33，11： | 1 |
| 3 | Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESLOVE): a 12- month randomized, controlled, double-masked, multicenter phase II study 显示文摘 | Massin P Bandello F Garweg JG | 2010 | Diabetes Care2010，33，11： | 1 |
| 4 | Immunopathology in ocular toxoplasmo- sis: facts and clues 显示文摘 | Garweg JG Candolfi E | 2009 | Mem Inst Oswaldo Cruz2009，104，2： | 1 |
| 5 | Pathophysiology of pro liferativevitreoretinopathy in retinal detachment显示文摘 | Garweg JG Tappeiner C Halberstadt M | 2013 | Surv Ophr thalmol2013，5，4： | 1 |
| 6 | Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study) : a 12-month, randomized, controlled, double-masked, multi- center phase II study 显示文摘 | Massin P Bandello F Garweg JG | 2010 | Diabetes Care2010，33，： | 1 |
| 7 | Pathophysiology of proliferative vitreoretinopathy in retinal detachment 显示文摘 | Garweg JG Tappeiner C Halberstadt M | 2013 | Surv Ophthalmol2013，58，4： | 1 |
| 8 | Macular edemain Kawasaki syndrome显示文摘 | Garweg JG Suter C Aebi-Ochsner C | 2012 | Graefes Arch Clin Exp Ophthalmol2012，250，7： | 1 |
| 9 | Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery:A prospective randomized placebo-controlled double-blind clinical trial显示文摘 | Koerner F Koerner-Stief bold U Garweg JG | 2012 | Graefes Arch Clin Exp Ophthalmol2012，250，7： | 1 |
| 10 | Intraocular microsporidiods due to Encephalitozoon cuniculi in a patient with idiopathic CD4^+ Tlymphocytopenia显示文摘 | Kodjikian L Garweg JG Nguyen M | 2005 | Int J Med Microbiol2005，294，8： | 1 |
| 11 | Safety and efficacy of ranibizumab in diabetic macu- lar edema ( RESOLVE Study ) : a 12-month, randomized, con- trolled, double-masked, mniticenter phase II study 显示文摘 | Massin P Bandello F Garweg JG Hansen LL Harding SP Lars- en M | 2010 | Diabetes Care2010，33，11： | 1 |
| 12 | Safety and efficacy of ranibi- zumab in diabetic macular edema( RESOLVE Study) : a 12 - month, randomized, controlled, double - masked, multicenter phase II study 显示文摘 | Massin P Bandello F Garweg JG | 2010 | Diabetes Care2010，33，11： | 1 |
| 13 | Safety and efficacy of ranibizumab in diabetic macutar edema (RESOLVE study): a 12-month, randomized, muhicenter phase II study显示文摘 | Massin P Bandello F Garweg JG | 2010 | controlled double-masked Diabetes Care2010，33，11： | 1 |
| 14 | Vitrectomy for juvenile uveitis:prognostic factors for the long-term functional outcome 显示文摘 | Trittibach P Koerner F Sarra GM Garweg JG | 2005 | Eye2005，20，2： | 1 |
| 15 | Update on vitrectomy for pediatric uveitis 显示文摘 | GARWEG J G BECKER M LOMMATZSCH A | 2007 | Klin Monatsbl Augenheilkd2007，224，6： | 1 |
| 16 | Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study):a 12-month,randomized,controlled,double-masked,multicenter phase Ⅱstudy显示文摘 | Massin P Bandello F Garweg JG | 2010 | Diabetes Care2010，33，： | 1 |
| 17 | Safety and efficacy of ranibizumab for diabetic macular edema (RESOLVE study):a 12-month,randomized,controlled double masked,multicenter phase Ⅱ study显示文摘 | Massin P Bandello F Garweg JG | | 0，，： | 1 |
| 18 | Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study):a 12-month,randomized,controlled,double-masked,multicenter phase Ⅱ study显示文摘 | Massin P Bandello F Garweg JG | 2010 | Diabetes Care2010，33，： | 1 |
| 19 | Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance显示文摘 | Peyron F Garweg JG Wallon M | 2011 | Pediatr Infect Dis J2011，30，7： | 1 |
| 20 | Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia显示文摘 | Damas P Garweg C Monchi M | 2006 | Crit Care2006，10，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员